| Document | Type | Published |
|---|---|---|
| Intralesional rituximab for localised pemphigus | D&T reviews | September 2025 |
| Adalimumab, infliximab, and ustekinumab in pyoderma gangrenosum | D&T reviews | August 2025 |
| Tofacitinib for pansclerotic morphoea | D&T reviews | June 2025 |
| Omalizumab for bullous pemphigoid | D&T reviews | June 2025 |
| Sodium zirconium cyclosilicate in children | D&T reviews | May 2025 |
| Daratumumab for haemolysis and drug-specific antigen desensitisation | D&T reviews | March 2025 |
